Bortezomib for multiple myeloma approved in Wales
Patients in Wales with multiple myeloma may now receive treatment with bortezomib (Velcade) through the NHS, the Welsh Minister for Health and Social Services has announced following recommendations from the All Wales Medicines Strategy Group.
The drug may be used for patients who have experienced disease progression despite already receiving two other therapies. Treatment must only be initiated and administered under the supervision of an appropriately qualified and experienced doctor.
The minister has also endorsed the AWMSG’s recommendation that the use of pegvisomant (Somavert) for the treatment of acromegaly should not be supported in Wales.
Citation: Electronicjuice URI: 10020530
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Electronicjuice, and is a leading provider of authoritative pharmaceutical information used throughout the world.